US FDA OK's Centocor Ortho's Zytiga for late-stage prostate cancer
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech won the US FDA's approval for Zytiga (abiraterone acetate) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior treatment with the chemotherapy agent docetaxel.